SNGX Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
Company profile
Ticker
SNGX, SNGXW
Exchange
Website
CEO
Christopher Schaber
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DOR BIOPHARMA INC, ENDOREX CORP, IMMUNOTHERAPEUTICS INC
SEC CIK
Corporate docs
IRS number
411505029
SNGX stock data
()
News
Soligenix To Receive $865,000 In Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
9 Mar 21
The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
4 Mar 21
12 Health Care Stocks Moving In Thursday's Pre-Market Session
4 Mar 21
Soligenix Shares Rally On Positive Preclinical Data For COVID-19 Vaccine Candidate
4 Mar 21
Soligenix Highlights Publication Of Pre-Clinical Studies For The CiVax COVID-19 Vaccine Program
4 Mar 21
Press releases
Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCL
7 Apr 21
Soligenix Announces Recent Accomplishments And Year-End 2020 Financial Results
30 Mar 21
Soligenix to Receive $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
9 Mar 21
Thinking about buying stock in Super League Gaming, Soligenix, Vascular Biogenics, BioLineRx, or electroCore?
4 Mar 21
Soligenix Announces Positive Progress in the Pre-clinical Development of its COVID-19 Vaccine
4 Mar 21
Investment data
Securities sold
Number of investors
Calendar
29 Mar 21
11 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from Soligenix earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 18.68M | 18.68M | 18.68M | 18.68M | 18.68M | 18.68M |
Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 1.83M | 1.55M | 1.37M | 954.54K |
Cash used (since last report) | n/a | n/a | 6.17M | 5.22M | 4.64M | 3.22M |
Cash remaining | n/a | n/a | 12.51M | 13.45M | 14.04M | 15.46M |
Runway (months of cash) | n/a | n/a | 6.8 | 8.7 | 10.2 | 16.2 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Jan 21 | Christopher J Schaber | Option Common Stock | Grant | Aquire A | No | No | 1.28 | 60,000 | 76.8K | 60,000 |
10 Dec 20 | Oreola Donini | Option Common Stock | Grant | Aquire A | No | No | 2.34 | 70,000 | 163.8K | 70,000 |
10 Dec 20 | Christopher J Schaber | Option Common Stock | Grant | Aquire A | No | No | 2.34 | 60,000 | 140.4K | 60,000 |
10 Dec 20 | Richard Straube | Option Common Stock | Grant | Aquire A | No | No | 2.34 | 40,000 | 93.6K | 40,000 |
10 Dec 20 | Jonathan L. Guarino | Stock Option COMMON STOCK | Grant | Aquire A | No | No | 2.34 | 40,000 | 93.6K | 40,000 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
9.5% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 35 |
Opened positions | 11 |
Closed positions | 5 |
Increased positions | 6 |
Reduced positions | 4 |
13F shares |
Current |
---|---|
Total value | 3.84M |
Total shares | 3M |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|---|---|
Vanguard | 909.16K | $1.16M |
Knoll Capital Management | 787.83K | $1.01M |
First Wilshire Securities Management | 350K | $448K |
Geode Capital Management | 128.4K | $164K |
California Public Employees Retirement System | 126.17K | $161K |
Gsa Capital Partners | 118.69K | $152K |
BLK Blackrock | 95.52K | $122K |
Plante Moran Financial Advisors | 71.66K | $92K |
NTRS Northern Trust | 48.47K | $62K |
VIRT Virtu Financial | 44.1K | $56K |
Financial report summary
?Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accommodate, accrual, add, admitted, advisory, affirmative, aim, alia, allege, alleged, annum, answered, apparent, apprising, arbitration, attestation, automation, Baltimore, Bank, BDS, biased, biorxiv, borrow, borrowed, borrowing, Boston, BSX, BTG, Burkholderia, carryover, case, cellular, Chase, choose, CiVaxTM, cleaning, companion, compendia, County, CoVaccine, Daavlin, dataset, deeper, deeply, default, deviation, distancing, downstream, drawn, EBS, EMOB, emulsified, energy, enriched, EPDG, EVD, exhausted, faulty, flow, flu, forgiven, fresh, Gaithersburg, GP, grow, House, HT, humoral, HyBiopharma, Hypericum, impede, imperative, incentivize, inter, intercepted, invoice, invoiced, IRS, Japanese, JPMorgan, judgement, Kura, lender, lien, loan, mandated, manipulation, manuscript, mask, mediated, Medison, Mercer, merchantability, methodology, monthly, moving, mucobuccal, NB, necessitate, notification, pandemic, paper, patch, Paycheck, payroll, penetrating, penetration, plaque, pledged, Pontifax, potency, PPP, prepayment, preprint, prototype, quickly, reading, remotely, renegotiate, repay, repayment, repurchasing, restructuring, revealed, sanitation, Simphotek, Singapore, social, SOM, sought, Spike, stored, strong, subset, substitute, subtopic, Sudan, talent, top, tranche, trend, turnover, uneven, unjustly, unpaid, unsecured, upstream, usage, venture, vi, vigorously, vii, viii, warranty, workplace, Zaire
Removed:
Amir, assigned, attainment, attribute, Ave, Brownlie, Carol, clarification, collection, dispositive, Ecker, Extensivein, FluorescentLightActivatedSyntheticHypericin, fourth, Frankenfield, guidance, inInternal, Intrexon, joined, Karen, Krumeich, Lancaster, legally, lesser, Lincoln, Managing, Master, modulatingINNATE, offered, ofHypericum, OrbeShield, owner, PA, Park, participated, predominantly, reserved, RiVax®and, RiVax®bulk, RiVax®testing, RiVax®under, ThermoVax®development, Wayne, Zolina®and
Financial reports
10-K
2020 FY
Annual report
29 Mar 21
10-Q
2020 Q3
Quarterly report
12 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
15 May 20
10-K
2019 FY
Annual report
30 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
14 May 19
10-K
2018 FY
Annual report
26 Mar 19
10-Q
2018 Q3
Quarterly report
9 Nov 18
Current reports
8-K
Regulation FD Disclosure
26 Jan 21
8-K
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
22 Dec 20
8-K
Soligenix Announces $20 Million Strategic Convertible Debt Financing Agreement with Pontifax Medison Debt Financing
16 Dec 20
8-K/A
Amendments to Articles of Incorporation or Bylaws
3 Dec 20
8-K
Submission of Matters to a Vote of Security Holders
25 Nov 20
8-K
Amendments to Articles of Incorporation or Bylaws
18 Sep 20
8-K
Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine
10 Sep 20
8-K
Entry into a Material Definitive Agreement
28 Aug 20
8-K
Soligenix Issues Corporate Update – Highlights Important Catalysts for Second Half of 2020
20 Jul 20
8-K
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
30 Apr 20
Registration and prospectus
S-3
Shelf registration
15 Jan 21
424B5
Prospectus supplement for primary offering
28 Aug 20
S-3/A
Shelf registration (amended)
14 Aug 20
S-3/A
Shelf registration (amended)
31 Jul 20
S-3
Shelf registration
17 Jul 20
424B5
Prospectus supplement for primary offering
10 Apr 20
424B5
Prospectus supplement for primary offering
20 Mar 20
424B5
Prospectus supplement for primary offering
3 Oct 18
424B4
Prospectus supplement with pricing info
28 Jun 18
S-1/A
IPO registration (amended)
20 Jun 18
Proxies
DEFA14A
Additional proxy soliciting materials
25 Nov 20
DEF 14A
Definitive proxy
6 Nov 20
PRE 14A
Preliminary proxy
23 Oct 20
DEFA14A
Additional proxy soliciting materials
13 Aug 20
DEFA14A
Additional proxy soliciting materials
7 Aug 20
DEF 14A
Definitive proxy
7 Aug 20
PRE 14A
Preliminary proxy
24 Jul 20
DEFA14A
Additional proxy soliciting materials
26 Jul 19
DEF 14A
Definitive proxy
26 Jul 19
DEFR14A
Revised proxy
17 Aug 18
Other
EFFECT
Notice of effectiveness
1 Feb 21
CORRESP
Correspondence with SEC
26 Jan 21
UPLOAD
Letter from SEC
21 Jan 21
EFFECT
Notice of effectiveness
31 Aug 20
CORRESP
Correspondence with SEC
25 Aug 20
CORRESP
Correspondence with SEC
30 Jul 20
UPLOAD
Letter from SEC
23 Jul 20
EFFECT
Notice of effectiveness
28 Jun 18
EFFECT
Notice of effectiveness
29 Nov 17
CORRESP
Correspondence with SEC
27 Nov 17
Ownership
4
SOLIGENIX / CHRISTOPHER J SCHABER ownership change
4 Jan 21
4
SOLIGENIX / Jonathan L. Guarino ownership change
11 Dec 20
4
SOLIGENIX / Richard Straube ownership change
11 Dec 20
4
SOLIGENIX / CHRISTOPHER J SCHABER ownership change
11 Dec 20
4
SOLIGENIX / Oreola Donini ownership change
11 Dec 20
4
SOLIGENIX / JEROME B ZELDIS ownership change
18 Sep 20
4
SOLIGENIX / ANTHONY GREGG LAPOINTE ownership change
18 Sep 20
4
SOLIGENIX / ROBERT J. RUBIN ownership change
18 Sep 20
4
SOLIGENIX / Diane L. Parks ownership change
18 Sep 20
4
SOLIGENIX / Diane L. Parks ownership change
19 Jun 20
Patents
APP
Utility
Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines
2 Dec 20
Disclosed is a stable immunogenic composition capable of eliciting a robust and durable immune response, comprising at least one antigen consisting of a filovirus glycoprotein and at least one nano-emulsion adjuvant which are co-lyophilized and can be reconstituted immediately prior to use.
APP
Utility
Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis
14 Oct 20
Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides.
APP
Utility
Topically Active Steroids for Use in Radiation and Chemotherapeutics Injury
20 May 20
Methods of delivering corticosteroids or metabolites thereof for treating and preventing tissue damage resulting from acute radiation injury in the gastrointestinal tract with locally effective therapeutic agents.
GRANT
Utility
Systems and methods for producing synthetic hypericin
6 Jan 20
Improved systems and methods for producing synthetic hypericin at high volume and high purity.
Reddit threads
Let me know what stocks you want to go green and I'll sell my shares! Works every time.
9 Apr 21
£GILD/$GULDF Guild Esports: David Beckham new BABY due to be listed on OTCQB
9 Apr 21
Friday FOMO: Let’s discuss what you’re picking up or letting go to end the week.
8 Apr 21
Anyone want to compare luggage? I’ll go first. My bags are as follows- 50k shares of $CBDL that’s down 85%, 5k shares of $OZSC that’s down 65%, and 25k shares of $CBDD that’s down 53%.
8 Apr 21
Anyone notice how most of the top DD posted on here this year, came around the peak of the stock and the stock has only fallen since?
8 Apr 21
Love seeing $SNGX and FDA in the same headline.
7 Apr 21
Who’s still bullish on GNUS ?
3 Apr 21
What’s one penny stock do you remember that fooled this community?
2 Apr 21
Why Does this Sub Suddenly Forget the Tickers that Were Supposed to be Millionaire-Makers a Few Months Back?
2 Apr 21
American Battery Metals Corporation (ABML) Adds Nick Copping, Technology Industry Veteran, to Advisory Board
1 Apr 21